

The Vth International Drug Discovery and Development Forum 2019

NEW TRENDS IN SMALL MOLECULE DRUG DISCOVERY: Artificial Intelligence, Cancer–Cell Vulnerabilities and Immunology



September 30 - October 2, 2019

The New Centre for Translational Biology

RI-MUHC, Glen site

Presented by:

The McGill-CIHR Drug Development Training Program





Centre universitaire de santé McGill Institut de recherche



McGill University Health Centre Research Institute

DAY 1 - MONDAY, SEPTEMBER 30, 2019

Educational Sessions in collaboration with the advanced technological platforms of the Centre for Translational Biology, the Research Institute of the MUHC



DAY 2 - TUESDAY, OCTOBER 1, 2019

8:30 - 9:00	AUDITORIUM ES1.1129	Registration Coffee		
9:00-9:15		DR. BERTRAND J. JEAN-CLAUDE Director of the McGill DDTP <i>Opening statement</i>		
SYMPOSIUM I - SMALL MOLECULE DISCOVERY				
9:15-9:45		DR. JIAN HUI WU Departments of Oncology and Medicine McGill University PRESENTATION TITLE: Discovery of Novel Compounds Targeting the N- terminal Domain of the Androgen Receptor for Castration-Resistant Prostate Cancer		
9:45-10:15		DR. MILDRED DUNCAN-AVECEDO Department of Chemistry University of South Florida PRESENTATION TITLE: PKC-ι and PKC-ζ are heavily responsible of upregulating epithelial-mesenchymal transition (EMT) and activating Vimentin to facilitate cellular motility in prostate cancer cell lines		
10:15-10:45		DR. ANNE-MARIE MES-MASSON Centre de recherche CHUM et Institut du cancer de Montréal PRESENTATION TITLE: Targeting genome instability as an essential vulnerability in ovarian cancer		

10:45-11:00 COFFEE BREAK			
11:00-11:30		DR. ALAIN NEPVEU Goodman Cancer Research Center and Departments of Oncology, Biochemistry and Medicine, McGill University PRESENTATION TITLE: Validation of a Therapeutic Target and Development of a High-Throughput Screen to Identify CUT Domain Inhibitors	
11:30-12:00		DR. ANNE MARINIER Director of Medicinal Chemistry, IRIC Université de Montréal PRESENTATION TITLE: Chemo-genomic screening in AML: a new approach to identify therapeutic strategies in cancer	
12:00 – 1:00 LUNCH BREAK			

SYMPOSIUM II – CHEMISTRY & IMMUNOLOGY

1:00-4:00

1:00-1:15		SESSION CHAIR DR. JOHN DIBATTISTA Professor, Department of Medicine McGill	
1:15-2:00		DR. LIJUN SUN Director, Center for Drug Discovery & Translational Research, Beth Israel Deaconess Medical Center Harvard Medical School PRESENTATION TITLE: Characterization of 3-Acylindoles as Potent AHR Agonists: Molecular Dynamics Simulation, Structure- Activity Relationship, and Therapeutic Application in Colitis	
2:00-2:45		DR. ORNELLA FRANZESE Department of Systems Medicine, School of Medicine, University of Rome Tor Vergata, Rome, Italy PRESENTATION TITLE: Drug-induced Xenogenization: new frontiers in cancer chemoimmunotherapy	
2:45 – 3:00 COFFEE BREAK			
3:00-3:45		DR. Kristen Smith Principal Scientist Immuno-Oncology, Discovery Bristol Myers Squibb USA PRESENTATION TITLE: Engineering therapeuticsLessons from building molecules that target the tumor microenvironment for immuno- oncology therapy	

NOV 23

oncology therapy

DAY 3 - WEDNESDAY, OCTOBER 2, 2019			
8:30- 9:00	AUDITORIUM	Registration	
	ES1.1129	Coffee	
9:00- 9:15		SESSION CHAIR	
		DR. NICOLAS MOITESSIER Professor, Department of Chemistry McGill	
		DR. SHAHAR KEINAN	
		Chief Scientific Officer,	
	Test	Cloud Pharmaceuticals, Inc.	
9:15-10:00		PRESENTATION TITLE:	
	The Th	ML and AI in the design of new drug lead compounds	
		DR. SHANRONG ZHAO	
10 00 10 17		Director, Computational Biology and Bioinformatics Pfizer Worldwide Research & Development	
10:00-10:45		PRESENTATION TITLE:	
		Advancements of RNA-seq technology and its application to	
		drug discovery	
10:45 – 11:00 COFFEE BREAK			
11:00-12:30		Oral presentations by trainees	
		(Performance Prizes to be presented at the Award Ceremony)	
12:30 – 1:30 LUNCH BREAK			

1:30-2:30	BLOC E	Academia-Industry Session
	Auditorium	
		DR. LANA E. JANES Venture Partner, adMare BioInnovations CDRD Centre for Drug Research & Development PRESENTATION TITLE: Design, synthesis and development of the next generation of radiopharmaceuticals as precision oncology therapeutics
		DR. JOSH POTTEL President and CEO Molecular Forecaster Inc. Distinguished DDTP Alumnus PRESENTATION TITLE: Accelerating Drug Discovery in Academia and Industry with Just a Few Clicks- Accessible Computational Workflows to Design Custom Experiments
2:30-4:30	BLOC E - ATRIUM	Poster Session & Commercial Exhibition
4:30-6:00	BLOC E Auditorium	AWARD CEREMONY GUEST OF HONOR DR. PHIL GOLD

A special thanks to our proud corporate sponsors

